Repositorio UFRO · Omeka S

l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

Primer Autor	Farias, Jorge G.
Co-autores	Tosta Perez, Maria Herrera Belen, Lisandra Letelier, Pablo Calle, Yolanda Pessoa, Adalberto
Título	l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review
Editorial	HUMANA PRESS INC
Revista	MEDICAL ONCOLOGY
Lenguaje	en
Resumen	l-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the l-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
Fecha Publicación	2023
Tipo de Recurso	artículo de revisión
doi	10.1007/s12032-023-02014-9
Formato Recurso	PDF
Palabras Claves	Acute lymphoblastic leukemia Asparaginase Antineoplastic agent Immunogenicity Hypersensitivity
Ubicación del archivo	http://dx.doi.org/10.1007/s12032-023-02014-9
Categoría OCDE	Oncología
Materias	Leucemia linfoblástica aguda asparaginasa Agente antineoplásico Inmunogenicidad Hipersensibilidad
Identificador del recurso (Mandatado-único)	artículo de revisión
Versión del recurso (Recomendado-único)	versión publicada
Derechos de acceso	restringido
Access Rights	restringido
Id de Web of Science	WOS:000969750300002
ISSN	1357-0560
Tipo de ruta	verde / dorado
Categoría WOS	Oncología
Referencia del Financiador (Mandatado si es aplicable-repetible)	ANID 21210710 CNPQ 301832/2017-0